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We reviewed the clinical courses of 159 patients between February 1967 and 
May 1995 for the purpose of examining the survival of patients who had 
pulmonary resection for metastatic colorectal cancer. The cumulative 
survivals at 5 years and 10 years were 40.5% and 27.7%, respectively. 
Fifteen patients (10%) were alive more than 10 years after the thoracotomy 
without any evidence of recurrence. The cumulative survival at 5 years for 
39 patients who had hepatic metastases before thoracotomy was 33%. There 
was a statistically significant difference in survival between patients with 
extrapulmonary metastases and those with only intrapulmonary metasta- 
ses before thoracotomy. The number of pulmonary metastases and the 
presence of hilar or mediastinal ymph node metastases affected posttho- 
racotomy survival. There was no significant difference in survival on the 
basis of sex, age, location of the primary cancer, size of the pulmonary 
tumors, mode of operation, or disease-free interval. Surgical treatment for 
pulmonary metastases from colorectal cancer in selected patients, even 
those who had hepatic metastases before thoracotomy, might improve 
prognosis. (J Thorac Cardiovasc Surg 1996;112:867-74) 
S urgical therapy has been attempted for meta- static lung tumors since Thomford, Woolner, 
and Clagett I published the principles for surgical 
treatment of metastatic lung tumors in 1965. As for 
resection of pulmonary metastases from colorectal 
cancer, documented 5-year survivals after resection 
of pulmonary metastases varied among institutions, 
ranging from 22% to 42%. 2-1° We 7 also reported our 
experience with 62 patients who underwent resec- 
tion of pulmonary metastases from colorectal cancer 
in 1988. In that series, we could not show that 
surgical resection of pulmonary metastases im- 
proved the cure rate. Furthermore, the significance 
of pulmonary metastatectomy for patients who had 
hepatic metastases before thoracotomy was un- 
known. In the present series, the clinical courses of 
159 patients were reviewed and followed for a much 
longer time. In addition, this study included 39 
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patients who had hepatic metastases before thora- 
cotomy. Therefore we believe it is possible to exam- 
ine the significance of pulmonary resection for met- 
astatic olorectal cancer more accurately than in our 
previous report. 
Patients and methods 
A total of 162 patients underwent pulmonary resection 
for metastatic lesions from colorectal cancer between 
February 1967 and May 1995 in the National Cancer 
Center Hospital in Japan. There were three hospital 
deaths within 30 days of the operation, and 159 patients 
were available for review in this study. Criteria for resec- 
tion of pulmonary metastases were as follows: (i) The 
patient must be able to tolerate the required surgical 
procedure and the remaining respiratory function is con- 
sidered to be good enough for ordinary life. (2) Unilateral 
or bilateral lung lesions can be seen on a chest roentgen- 
ogram or a computed tomographic s an and those lesions 
presumably could be completely resected. (3) There are 
no distant metastases without pulmonary lesions and 
there was no evidence of local recurrence of the primary 
cancer. (4) It is possible to completely remove both 
hepatic and pulmonary metastases, if present. 
Table I summarizes the characteristics of the 159 pa- 
tients. We divided tile patients into three groups. Group A 
consisted of 111 patients who had no extrapulmonary 
metastatic lesions before thoracotomy. Group B included 
39 patients who had hepatic metastases b fore or at the 
time of thoracotomy. Ten patients who underwent simul- 
taneous resection of pulmonary and hepatic metastases 
were included in group B. Group C was composed of nine 
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Table I. Characteristics of 159 patients who 
underwent resection of pulmonary metastases from 
colorectal cancer 
No. of patients 
Sex 
Male 95 
Female 64 
Age (yr) 
Average 58.7 
Range 28-82 
Location of primary cancer 
Colon 82 
Ascending 19 
Transverse 4 
Descending 4 
Sigmoid 55 
Rectum 73 
Unknown 4 
Grade of primary tumor 
Dukes' A 11 
Dukes' B 30 
Dukes' C 64 
Unknown 54 
No. of Pulmonary metastases 
Solitary 107 
Multiple 52 
Site of metastases before thoracotomy 
No metastases (group A) 111 
Liver (group B) 39 
Local (group C) 9 
Location of pulmonary metastases 
Left lung 65 
Right lung 62 
Both 32 
Mode of operation 
Pneumonectomy 7 
Lobectomy 85 
Wedge or segmental resection 67 
patients who had undergone r section of local recurrence 
before thoracotomy (Table I). 
The medical charts were examined for age; sex; stage 
and grade of the primary cancer; location, number, and 
size of the pulmonary metastases; mode of the operation 
(Table I). Also evaluated were the presence of hepatic 
metastasis or local recurrence (or both) and disease-flee 
interval (DFI) between resection of the primary lesion 
and clinical detection of pulmonary metastases. The sur- 
vival after thoracotomy was estimated by the method of 
Kaplan and Meier. n The significance of each prognostic 
factor was determined by the log-rank test. s2 
Results 
Five of the 159 patients (3.1%) underwent incom- 
plete resection for pulmonary metastases because of 
numerous mall lesions (four patients) or involve- 
ment of the main bronchus by metastatic lymph 
nodes (one patient). 
The cumulative survivals at 5 years and 10 years 
were 40.5% and 27.7%, respectively (Fig. 1). Fifteen 
of the 16 10-year survivors were alive with no 
evidence of cancer ecurrence and only one patient 
died of metastatic disease. Seven of the 37 patients 
who survived more than 5 years died of metastatic 
disease, and five patients died without recurrence. 
Two patients were alive with recurrent cancer at the 
time of this report. The other 23 5-year survivors 
were free of disease. 
Table II shows survivals 5 years after thoracotomy 
based on potential prognostic factors. The cumula- 
tive survival for patients in group A was 44.9% at 5 
years, but for patients in group B it was 33.0%. The 
difference between these two groups was statistically 
significant. The cumulative survival for patients in 
group C at 5 years was 25.0%. There was also a 
statistically significant difference between group A 
and group C but no significant difference between 
group B and group C (Table II, Fig. 2). 
In group A, the Cumulative survival for 78 patients 
with a solitary pulmonary metastasis was 52.5% at 5 
years, whereas that for 33 patients with multiple 
pulmonary metastases was 25.5% (Fig. 3). The 
difference between these two groups was statistically 
significant (p = 0.019). Wedge or segmental resec- 
tion was adopted to preserve respiratory function, 
especially in the patients with multiple metastases. 
Fourteen patients (42%) with multiple metastases in 
group A underwent limited resection, 16 patients 
(49%) had lobectomy, and three patients (9%) had 
pneumonectomy. Among the patients with a solitary 
metastasis n group A, 23 patients (29%) underwent 
limited resection, 52 (66%) had lobectomy, and 
three (4%) pneumonectomy. For the patients with a 
solitary metastasis, the cumulative survivals for the 
lobectomy and limited resection groups were 45.6% 
and 73.3%, respectively, at 5 years (p = 0.080) (Fig. 
4). The intrapulmonary ecurrence rates after lim- 
ited resection for the patients with multiple tumors 
and a solitary tumor were 50% (7/14) and 39% 
(9/23), respectively. In this series, we could not 
examine marginal recurrence after limited pulmo- 
nary resection. The cumulative survival for 52 pa- 
tients with a DFI of more than 24 months was 50.1% 
at 5 years, whereas that for 57 patients with a DFI of 
less than 24 months was 40.6%. There was no 
significant difference in survival based on DFI for 
the patients in group A (p = 0.486). 
In group B, the 5-year survival even for the 
patients who had hepatic metastases before thora- 
cotomy was 33.0%. Twenty patients had a solitary 
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Fig. 1. Kaplan-Meier survival curve for all 159 patients who underwent resection of pulmonary metastases 
from colorectal cancer. 
100 
80 
v 60 
~- 40 
"7, 
20 
0 
l - Group A (n = 111) 
X Group B (n = 39) 
@ Group C (n = 9) 
I t I I [ [ 
0 5 10 15 20 25 30 
years after thoracotomy 
Fig. 2. Kaplan-Meier survival curves based on the three groups. Group A, Patients without extrathoracic 
metastasis before thoracotomy. Group B, Patients with a history of hepatic metastases. Group C, Patients 
with a history of local recurrences, n Number of patients. 
hepatic metastasis, three patients had two hepatic 
metastases, and four patients had three. In 12 
patients the number of hepatic metastases was un- 
known. There was no significant difference in the 
survivals between the group of the patients with 
solitary hepatic metastases and those with multiple 
metastases (p = 0.26). Two of the four patients who 
survived more than 5 years died of metastatic dis- 
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Fig. 3. Kaplan-Meier survival curves for the patients with a solitary metastasis and the patients with 
multiple metastases in group A (p = 0.019). 
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Fig. 4. Kaplan-Meier survival curves for the patients who underwent limited resection and the patients 
who underwent lobectomy in group A with a solitary metastasis (p = 0.08). n, number of patients. 
ease and one  patient was alive with recurrent can- 
cer. The other patient was free of disease. The only 
statistically significant difference in survival for the 
patients in group B was that concerning the number  
of pulmonary metastases. The cumulative survival 
for 22 patients with a solitary pulmonary metastasis 
was 43.7% at 5 years, whereas that for 17 patients 
with multiple pulmonary metastases in group B was 
22.3% (p = 0.047). 
In this series, hilar or mediastinal lymph nodes of 
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Table II. Survivals 5 years after thoracotorny on the basis of potential prognostic factors 
Five-year sur~'ivaI 
Variables No. of patients (%) p Value 
Sex 
Male 95 37.3 0.639 
Female 64 46.1 
Age 
->65 yr 52 55.9 0,222 
<65 yr 107 34.0 
Location of primary cancer 
Colon 82 42.1 0.801 
Rectum 73 39.1 
Grade of primary tumor 
74.1 ]* 0.033* Dukes' A 11 $ 35.2 ].~ 
Dukes' B 30 0.488t 
Dukes' C 64 32.5 0.011:~ 
Site of metastases before thoracotomy 
No metastases (group A) 111 [ 44.9 ] ,  0.009* 
Liver (group B) 39 ~ 33.0 0.282? 
Local (group C) 9 [ 25.0 ]'~ 0.012~: 
Size of metastatic lesion ~ 
->3.0 cm 73 35,3 0.078 
<3.0 cm 79 46.8 
No. of pulmonary metastases 
Solitary 107 48.4 0.003 
Multiple 52 23.4 
Mode of operation 
46.7 ]* 0.489* Wedge or segmental resection 67 +~ 39.8 0.572? 
Lobectomy 85 
Pneumonectomy 7 47.6 ]I" 0.703; 
Hilar and/or mediastinal lymph nodes 
metastases b 
Negative 85 50.0 0.0004 
Positive 15 6.7 
~The size was unknown in seven patients. 
bLymph node invoNement was not assessed in59 patients. 
*, ?, ~, The p value with each symbol indicates the statistical comparison ofsurvival between the corresponding two groups with the symbol out of three. 
100 patients were dissected or sampled and lymph 
node metastasis from the pulmonary metastases was 
observed in 15 patients (Table II). One of these 15 
patients was alive after more than 5 years, but she 
had been receiving chemotherapy for bone metas- 
tasis. The other 14 patients died of metastatic 
disease within 5 years after the thoracotomy. There 
was a statistically significant difference in survival 
between the patients who had hilar or mediastinal 
lymph node metastases and those who did not (Fig. 5). 
Although the number of patients whose primary 
cancer was Dukes' grade A was small (11/159), the 
5-year survival for these patients was 74.1%. Dukes' 
A classification was a favorable prognostic factor 
(Table II). 
We v previously reported that there is a significant 
difference in survival on the basis of the size of 
puhnonary metastatic lesions, but in this series the 
size of the metastatic tumor had no significant 
bearing on the survival (Fig. 6). No significant 
differences in survival were based on sex, age, loca- 
tion of the primary lesion, or extent of the operation 
(Table II). 
In this series, there were three favorable prognos- 
tic factors or criteria: (1) The lung should be the first 
metastatic site after resection of the primary cancer; 
(2) there should be only one metastatic tumor at the 
time of thoracotomy; and (3) there should be no 
metastatic hilar or mediastinal lymph nodes. The 
survivals at 5 years and 10 years for 69 patients who 
satisfied these three criteria were 62.1% and 47.0%, 
respectively (Fig. 7). The survivals at 5 years and 10 
years for the 90 patients who did not satisfy these 
criteria were 22.4% and 10.6%, respectively. There 
was a statistically significant difference between 
these two groups (p < 0.0001). 
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Fig. 5. Kaplan-Meier survival curves for patients with or without hilar and/or mediastinal lymph node 
metastases (p = 0.0004) n, Number of patients. 
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Fig. 6. Kaplan-Meier survival curves according to the size of the pulmonary metastasis (>3.0 cm vs. <3.0 
cm) (p = 0.078). n, Number of patients. 
Discuss ion  
The cumulative surviyals for the 159 patients 
involved in this study at 5 years and at 10 years were 
40.5% and 27.7%, respectively. These survivals are 
not dramatically different from those in earlier 
reports. 21° Wagner and colleagues 13 reported on 
the significance of resection of hepatic metastases 
from colorectal cancer based on the difference be- 
tween the clinical courses of patients with untreated 
metastases and those with resected metastases. 
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Fig. 7. Kaplan-Meier survival curves for 69 patients who satisfied the favorable three criteria given in the 
text and 90 patients who did not (p < 0.0001). 
There have been no similar reports on pulmonary 
metastases or any prospective trials. We 7 also sug- 
gested that the survival of the individual patient 
might be predetermined by the biologic behavior of 
the primary tumor, or "length bias." Therefore is it 
not possible to determine the significance of resec- 
tion of pulmonary metastases from colorectal can- 
cer. Although several patients died of metastatic 
tumors in 5 to 10 years, 15 patients in this series 
were alive after more than 10 years with no evidence 
of cancer recurrence. In addition, 69 patients with 
favorable factors in our experience had a cumulative 
survivals of 62.1% and 47.0% at 5 years and 10 
years, respectively (Fig. 7). In light of these results, 
surgical treatment for pulmonary metastases from 
colorectal cancer not only may have some survival 
benefit but also may allow potential cure in selected 
patients. 
Although Thomford, Wollner, and Clagett 1 ex- 
cluded patients with extrapuhnonary metastases as 
candidates for thoracotomy, there have been several 
reports about pulmonary resection for patients with 
extrapulmonary metastases. McAfee and col- 
leagues s said that the presence of resectable x- 
trapulmonary metastases before or at the time of 
thoracotomy was not associated with a decreased 
survival. Yano and colleagues 9 also reported that 
the presence of resectable or controllable hepatic 
metastases did not decrease the survival. In our 
series, the presence of extrapulmonary metastases 
was the unfavorable prognostic factor. This differ- 
ence was probably caused by the differences in the 
number of patients, the periods of follow-up, and 
the indications for resection. Muhe, Gall, and 
Angemann 14 reported the follow-up data of 67 
patients who underwent resection for pulmonary 
metastases from colorectal cancer. That study in- 
cluded 18 patients who had hepatic metastases 
before thoracotomy, and their 5-year survival was 
only 18%. The 5-year survival for patients who 
underwent hepatic resection for metastases for colo- 
rectal cancer ranged from 25% to 47.9%. 15-17 In 
light of these results, metastatectomy might be 
beneficial only when the metastasis i  confined to 
the organ that is the first hematogenic metastatic 
filter from the primary tumor, and it might be of no 
effect when the secondary metastasis from the first 
filter organ occurs or when two filter organs of 
different pathways are affected. However, in our 
series the cumulative survival at 5 years for 22 
patients with a solitary metastasis n group B was as 
high as 43.7%. At present, it appears that a patient 
with a solitary pulmonary metastasis potentially 
benefits from pulmonary resection even when there 
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is a history of hepatic metastasis. Regarding multi- 
ple pulmonary metastases in patients who have or 
had hepatic metastases, the significance of surgical 
treatment is still unknown. Therefore a prospective 
studies hould be done to determine the significance 
of resection of pulmonary metastases for patients 
with extrapulmonary metastases. 
As for the extent of pulmonary resection, our 
preliminary analysis in the middle of the 1980s 
showed a high incidence (about 30%) of local 
recurrence at the resected margin in the cases of 
limited resection. In view of this, we attempted to 
perform lobectomy in all patients with solitary pul- 
monary metastases who were expected to have a 
favorable prognosis. However, the results of this series, 
as well as of our former report, 7show that the extent 
of pulmonary resection did not appear to affect the 
prognosis. Limited resection may be a preferable 
procedure for pulmonary metastatectomy if there is an 
adequate surgical margin around the tumor. 
Cahan, Gastro, and Hajdu ~s found that 10 of 20 
patients who underwent resection for pulmonary 
metastases from colon had hilar or mediastinal 
lymph node metastases (or both). On the basis of 
this finding, they advocated lobectomy and lymph 
node removal for these metastatic lesions. However, 
in their series, only one patient with metastatic 
lymph nodes survived more than 5 years. In our 
series, resecting pulmonary metastases was not 
worth while in the patients who had hilar or medi- 
astinal ymph nodes metastases, because the dissec- 
tion of hilar and mediastinal lymph nodes could not 
control the disease. We believe that pulmonary 
metastasis with subsequent lymph node metastasis i  
in advance of the first step in the "metastatic 
cascade" advocated by Viadana, Bross, and Pick- 
ren. 19 Therefore valuation of hilar and mediastinal 
lymph nodes is important, and only sampling of 
those lymph nodes should be attempted to predict 
the clinical course after thoracotomy. 
In conclusion, we believe that pulmonary resec- 
tion for metastatic tumors from colorectal cancer 
can improve survival. Furthermore, there appears to 
be a chance for cure in selected patients with a 
solitary pulmonary metastasis. Pulmonary met- 
astatectomy has a potential survival benefit to the 
patient who has multiple pulmonary metastases or 
who had hepatic metastases before thoracotomy. 
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